Joseph R. Moskal

Corporate Officer/Principal at Northwestern University

73 year

Consumer Services

Health Technology

Joseph R. Moskal active positions

Companies	Position	Start	End
Northwestern University Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses	Corporate Officer/Principal	-	-

Companies	Position	Start	End
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	-	-
APTINYX	Chief Tech/Sci/R&D Officer	2015-06-30	-
	Founder	2015-05-31	-
	Corporate Officer/Principal	-	-
Naurex, Inc. Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.	Chief Tech/Sci/R&D Officer	2011-05-12	-
	Founder	2005-12-31	-

University of Notre Dame

Doctorate Degree

International

United States

Operational

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	2
Founder	2

Sectoral

Consumer Services	4
Health Technology	3

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	1
APTINYX	Health Technology

Private companies	1
Naurex, Inc. Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.	Health Technology

Private companies

Health Technology